Φορτώνει......
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
Reactivated androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC). Novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms o...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Pharmacol Ther |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4715745/ https://ncbi.nlm.nih.gov/pubmed/26331358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.256 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|